| Literature DB >> 30988601 |
Charles Christian Adarkwah1,2,3, Nikita Jegan1, Monika Heinzel-Gutenbrunner4, Felicitas Kühne5,6, Uwe Siebert5,6,7, Uwe Popert8, Norbert Donner-Banzhoff1, Sarah Kürwitz1,9.
Abstract
BACKGROUND: Shared decision-making is a well-established approach to increasing patient participation in medical decisions. Increasingly, using lifetime-risk or time-to-event (TTE) formats has been suggested, as these might have advantages in comparison with a 10-year risk prognosis, particularly for younger patients, whose lifetime risk for some events may be considerably greater than their 10-year risk. In this study, a randomized trial, the most popular 10-year risk illustration in the decision-aid software Arriba (emoticons), is compared with a newly developed TTE illustration, which is based on a Markov model. The study compares the effect of these two methods of presenting cardiovascular risk to patients on their subsequent adherence to intervention.Entities:
Keywords: Arriba; adherence; cardiovascular disease; decision aid; lifetime risk; randomized trial; risk assessment; risk perception; shared decision-making 10-year prognosis; time to event
Year: 2019 PMID: 30988601 PMCID: PMC6441552 DOI: 10.2147/PPA.S197545
Source DB: PubMed Journal: Patient Prefer Adherence ISSN: 1177-889X Impact factor: 2.711
Figure 1Flowchart of participation.
Abbreviations: GP, general practitioner; TTE, time to event.
Characteristics of the study population (n=294)
| Emoticons | Time to event | ||
|---|---|---|---|
| Age (years), mean (SD) | 58.24 (10.61) | 58.20 (10.90) | 0.973 |
| Immigrants, n (%) | 10 (7.2) | 13 (8.7) | 0.669 |
| Low level of education, | 65 (45.1) | 64 (42.7) | 0.725 |
| Sex (male), n (%) | 88 (61.1) | 82 (54.7) | 0.289 |
| Known hypertension, n (%) | 36 (25) | 44 (29.3) | 0.433 |
| Total cholesterol >200 mg/dL, n (%) | 98 (68.1) | 112 (74.7) | 0.245 |
| HDL cholesterol <40 mg/dL, n (%) | 25 (17.7) | 20 (13.3) | 0.418 |
| Known diabetes, n (%) | 43 (29.9) | 40 (26.7) | 0.605 |
| Current smokers, n (%) | 39 (27.1) | 41 (27.3) | 1 |
| Male age >55 years/female age >65 years, n (%) | 67 (46.5) | 69 (46.0) | 1 |
| Known vascular disease, | 15 (10.6) | 14 (9.3) | 0.846 |
| Family history of vascular disease, | 47 (32.6) | 50 (33.3) | 0.902 |
| Hypertension medication, n (%) | 83 (57.6) | 73 (48.7) | 0.130 |
| Mean number of risk factors | 3.11 (1.57) | 3.05 (1.33) | 0.703 |
| GPs with Arriba experience, n (%) | 15 (10.4) | 17 (11.3) | 0.853 |
| Numeracy (correct answers), mean (SD) | 1.1 (0.80) | 1.1 (0.84) | 0.937 |
Notes:
Defined as no general certificate of secondary education;
evidence of coronary heart disease, stroke, or peripheral arterial occlusive disease;
at least one first-degree relative with coronary heart disease before age 55 years (men) and 65 years (women);
GPs had used Arriba.
Abbreviations: GP, general practitioner; HDL, high-density lipoprotein.
Figure 2Frequency distribution of number of interventions discussed and agreed upon per patient per study arm.
Mean adherence in relation to number of interventions discussed
| Interventions, n | Mean | n | SD | ||
|---|---|---|---|---|---|
| Emoticons | 1 | 0.85 | 33 | 0.57 | 0.025 |
| 2 | 1.20 | 43 | 0.46 | ||
| 3 | 1.04 | 35 | 0.34 | ||
| 4 | 0.97 | 17 | 0.20 | ||
| 5 | 1.08 | 11 | 0.24 | ||
| 6 | 1.00 | 4 | 0.14 | ||
| Time to event | 1 | 1.19 | 32 | 0.59 | 0.210 |
| 2 | 1.00 | 46 | 0.35 | ||
| 3 | 1.01 | 30 | 0.27 | ||
| 4 | 1.05 | 14 | 0.17 | ||
| 5 | 0.87 | 9 | 0.20 | ||
| 6 | 1.06 | 6 | 0.09 |
Note:
Global value on ANOVA.
Figure 3Frequency distribution of adherence score per study arm.
Risk perception and self-rated importance of avoiding a cardiovascular event over time, depending on risk representation
| Mean | n | SD | ||
|---|---|---|---|---|
| Emoticons | ||||
| Risk perception at baseline | 4.08 | 143 | 2.366 | 0.266 |
| Risk perception at follow-up (3 months) | 3.88 | 143 | 1.915 | |
| Importance at baseline | 8.84 | 144 | 2.399 | <0.0005 |
| Importance at follow-up (3 months) | 9.92 | 144 | 0.383 | |
| Time to event | ||||
| Risk perception at baseline | 5.14 | 146 | 2.805 | 0.002 |
| Risk perception at follow-up (3 months) | 4.40 | 146 | 2.043 | |
| Importance at baseline | 9.05 | 147 | 1.975 | <0.0005 |
| Importance at follow-up (3 months) | 9.81 | 147 | 0.612 | |
Note:
Paired t-tests.